| Suspended | Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysp NCT06888323 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell NCT06928662 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810 | Mayo Clinic | Phase 1 |
| Recruiting | Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients Wi NCT06484062 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Pati NCT06572631 | City of Hope Medical Center | Phase 1 |
| Suspended | Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refr NCT06454409 | City of Hope Medical Center | Phase 1 |
| Recruiting | TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes W NCT03816319 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia NCT06399640 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Active Not Recruiting | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leu NCT05146739 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome NCT05564650 | Thomas Jefferson University | Phase 1 |
| Terminated | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplast NCT04874194 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who NCT05030675 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acu NCT04752163 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid NCT04250051 | Northwestern University | Phase 1 |
| Recruiting | CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatmen NCT04375631 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or C NCT04550442 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patien NCT04239157 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Synd NCT03953898 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or NCT04487106 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia an NCT04128748 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or My NCT03969446 | City of Hope Medical Center | Phase 1 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Terminated | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome NCT04160052 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Le NCT04013880 | Vanderbilt-Ingram Cancer Center | Phase 1 / Phase 2 |
| Terminated | Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelody NCT03772925 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refract NCT03813147 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndr NCT03630991 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After NCT03326921 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients W NCT03096782 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute M NCT02890329 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome NCT02392572 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leuk NCT01892371 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |